ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: SA-PO428

Comparison between Lung Ultrasonography and Clinical Assessment for Volume Control in Patients on Chronic Hemodialysis

Session Information

Category: Dialysis

  • 801 Dialysis: Hemodialysis and Frequent Dialysis

Author

  • Kongpetch, Sawinee, Khon Kaen University, Nai Mueang, Khon Kaen, Thailand
Background

The management of volume overload to achieve dry weight improves hypertension and survival in hemodialysis patients. Several techniques are used for volume assessment, however, interventional studies with fluid-guided management are scarce. We aimed to compare between lung ultrasonography (LUS) and clinical assessment to guide volume reduction for blood pressure (BP) control.

Methods

The randomized control trial was conducted in chronic hemodialysis patients between December 2018 and March 2023. The study group was performed LUS every week for total 8 weeks to assess volume status and reduction of dry weight 0.05 and 0.1 kg/10-kg body weight if LUS score 16-30 and > 30, respectively. The control group was reduced dry weight as clinically indicated. Group-blindly investigators measured bioelectrical impedance analysis (BIA) in all participants at the start and finish times of study to assess the optimal dry weights and these results were concealed. At weeks 4 and 8, both groups were compared BP levels, dry weight achievement, cardiothoracic ratio evaluated by chest x-ray, number of antihypertensive drugs, N-terminal-pro-Brain Natriuretic Peptide (NT-proBNP) levels and intradialytic complications.

Results

A total of 83 patients with a mean age of 62.6±13 years and 72.5% male were randomized into the LUS group (n=41) and the clinical group (n=42). Baseline levels of the LUS vs. clinical groups were (a) systolic BP 146±17 vs. 143±11 mmHg, (b) cardiothoracic ratio 0.57±0.06 vs. 0.53±0.06, (c) median NT-proBNP 3,758 vs. 3,607 pg/mL. At weeks 4 and 8, systolic BP adjusted with baseline levels were significantly lower in the LUS groups (weeks 4; 134±13 vs.142±16, p <0.01 and weeks 8; 137±18 vs. 143±15, p=0.01). At the end of study, the LUS group also had (a) higher proportion of participants requiring less antihypertensive drugs (60% vs. 10%, p=0.002), (b) greater percentage of median cardiothoracic ratio reduction (-1.78% vs. 0.98%, p=0.03) and (c) closer levels of optimal dry weight obtained by BIA, than the clinical group. Incidences of intradialytic complications were similar in both groups.

Conclusion

LUS was helpful in volume assessment and fluid-guided management to achieve dry weight and control blood pressure. Further larger clinical trials should be conducted to prove benefit in survival of HD patients.

Funding

  • Government Support – Non-U.S.